Results 251 to 260 of about 700,365 (275)
Some of the next articles are maybe not open access.

Illumina, Inc.

Pharmacogenomics, 2005
Illumina, Inc., based in San Diego (CA, USA), is a genomics tool company that develops and markets integrated array-based systems and assays for a broad range of applications including genotyping, gene expression and epigenetics. Product offerings range from focused assay sets (up to 1,536 multiplexed assays) to whole-genome analysis (>100,000 assays ...
Frank J, Steemers, Kevin L, Gunderson
openaire   +2 more sources

Ombra, che illumina.

2023
"Lunario" is one of Guidi's last books. This is undoubtedly the artist's least characteristic work – an unusual project for a photographer of streets and sites of memory, of the outskirts and of domestic spaces. Here Guidi - a visual phenomenologist of the surroundings, the variations in the appearances of which he explores in precise intervals of time
openaire   +2 more sources

Small-Scale Illumina Library Preparation Using the Illumina Nextera XT DNA Library Preparation Kit

Cold Spring Harbor Protocols, 2023
Here, we describe a protocol for a scaled-down version of a genomic DNA (gDNA)-fragmentation and tagmentation reaction using the Illumina Nextera XT DNA Library Preparation Kit. UsingStaphylococcus aureusas an example,which has a genome size of ∼3 Mb, we show how 24 different samples can be pooled for a typical paired-end Illumina high-throughput ...
Merve S. Zeden, Angelika Gründling
openaire   +2 more sources

Best Practices for Illumina Library Preparation

Current Protocols in Human Genetics, 2019
AbstractIn this unit, we describe a set of protocols and recommendations for Illumina library preparation. We review best practices in template quantitation methods; template fragmentation methodologies; solid‐phase reverse‐immobilization cleanup, including buffer exchange and size selection; end repair, A‐tailing, and adapter ligation; indexing ...
Iraad F, Bronner, Michael A, Quail
openaire   +2 more sources

Illumina, PacBio part ways

C&EN Global Enterprise, 2020
Faced with resistance from antitrust authorities concerned about reduced competition, Illumina has dropped plans to acquire its next-generation DNA-sequencing (NGS) rivalPacific Biosciences of Cali...
openaire   +1 more source

Multiplex Illumina Sequencing Using DNA Barcoding

Current Protocols in Molecular Biology, 2013
AbstractThe amount of sequence obtained by modern sequencing machines greatly exceeds the sequencing depth requirements of many experiments, especially those involving organisms with small genomes. In the interest of economy and efficiency, various strategies have been developed for multiplexing, in which samples are uniquely tagged with short ...
Koon Ho, Wong   +2 more
openaire   +2 more sources

Illumina universal bead arrays.

Methods in enzymology, 2006
This chapter describes an accurate, scalable, and flexible microarray technology. It includes a miniaturized array platform where each individual feature is quality controlled and a versatile assay that can be adapted for various genetic analyses, such as single nucleotide polymorphism genotyping, DNA methylation detection, and gene expression ...
Jian-Bing, Fan   +9 more
openaire   +1 more source

Genotype Calling for the Illumina Platform

2011
Genome-wide association studies have been made possible because of advancements in the design of genotyping technologies to assay a million or more single nucleotide polymorphisms (SNPs) simultaneously. This has resulted in the introduction of automated and unsupervised statistical approaches for translating the probe hybridization intensities into the
openaire   +2 more sources

Illumina backs three genomics startups

Nature, 2014
Sequencing firm's incubator programme aims to develop its technology for wider applications.
openaire   +1 more source

Roche Bids To Buy Illumina

Chemical & Engineering News Archive, 2012
Roche has made a hostile move to acquire Illumina for $5.7 billion in cash. The Swiss drugmaker says it made the bid after Illumina, a provider of gene-sequencing technology, refused to participate in “substantive discussions” about a friendly acquisition.
openaire   +1 more source

Home - About - Disclaimer - Privacy